Bevacizumab: Is the lower the better for glioblastoma patients in progression? - Hallo friendsTOP POLENNEWS, In the article you read this time with the title Bevacizumab: Is the lower the better for glioblastoma patients in progression?, We have prepared this article for you to read and retrieve information therein. Hopefully the contents of postings Article cultur, Article economic, Article health, Article news, Article politique, Article sport, We write this you can understand. Alright, good read.

Title : Bevacizumab: Is the lower the better for glioblastoma patients in progression?
link : Bevacizumab: Is the lower the better for glioblastoma patients in progression?

Bevacizumab: Is the lower the better for glioblastoma patients in progression?

A very interesting study confirming previous reports on the possibility of using low doses of bevacizumab.

Unfortunately, the full article is not yet available:

http://sci-hub.tw/https://linkinghub.elsevier.com/retrieve/pii/S0007455118302315

https://www.ncbi.nlm.nih.gov/pubmed/30301554

METHODS:

From September 2013 to August 2016, we recruited patients with progressive glioblastoma, whatever the previous treatments. We compared a routine control group (CG) of ten mg/kg, to a low dose group (LDG) composed of 5 subgroups: G5: five mg/kg, G4: four mg/kg, G3: three mg/kg, G2: two mg/kg, G1: one mg/kg; each patient was treated with the same dose every two weeks.

RESULTS:

Fifty-three patients were treated: 20 women and 33 men, 24 in the CG and 29 in the LDG. The median age at diagnosis was 62 years [35.0-77.0]. No statistical difference was found in overall survival either for the CG or the LDG (P=0.086) or among groups (P=0.251), with even a trend toward improvement for LDG: 62 weeks [20-145] versus 73 weeks [18-178]. The median progression free survival was comparable: 19.5 weeks [6.0-54.0] for the CG and 15.0 weeks [0.0-134.0] for the LDG (P=0.221). Bevacizumab was stopped either due to progression (45.1%) or toxicity (52.9%), without significant differences between doses but maybe less toxicities in the LDG (16.7% for toxicity in G1).

DISCUSSION:

Use of bevacizumab at progression at lower than usual doses seems to give the same results as the standard dose without giving additional toxicity.

Thus Article Bevacizumab: Is the lower the better for glioblastoma patients in progression?

That's an article Bevacizumab: Is the lower the better for glioblastoma patients in progression? This time, hopefully can give benefits to all of you. well, see you in posting other articles.

You are now reading the article Bevacizumab: Is the lower the better for glioblastoma patients in progression? with the link address https://polennews.blogspot.com/2018/10/bevacizumab-is-lower-better-for.html

Tweet

Subscribe to receive free email updates: